Beta Bionics Inc(BBNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 7:30 PM ET (Korea 9/19 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.65 | Insider Own | 16.8% | Shs Outstand | 45.0M | Perf Week | 32.11% |
| Market Cap | 0.98B | Forward P/E | - | EPS next Y | -6.52% | Insider Trans | -2.22% | Shs Float | 37.4M | Perf Month | 9.4% |
| Enterprise Value | 0.81B | PEG | - | EPS next Q | -0.54 | Inst Own | 97.19% | Short Float | 25.12% | Perf Quarter | 57.71% |
| Income | -0.07B | P/S | 8.28 | EPS this Y | -15.33% | Inst Trans | -5.03% | Short Ratio | 7.3 | Perf Half Y | 102.69% |
| Sales | 0.12B | P/B | 3.84 | EPS next 5Y | 3.73% | ROA | -23.45% | Short Interest | 9.40M | Perf YTD | -28.16% |
| Book/sh | 5.7 | P/C | 5.45 | EPS past 3/5Y | -6.13% - | ROE | -26.16% | 52W High | -33.08% ($32.71) | Perf Year | -5.03% |
| Cash/sh | 4.01 | P/FCF | - | Sales past 3/5Y | 724.29% - | ROIC | -27.93% | 52W Low | 148.75% ($8.80) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.69% | Gross Margin | 58.31% | Volatility(W/M) | 13.96% 8.09% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 6.81 | Sales Y/Y TTM | 52.54% | Oper. Margin | -69.75% | ATR (14) | 1.56 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.96 | EPS Q/Q | -35.38% | Profit Margin | -61.32% | RSI (14) | 64.72 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.88 | Sales Q/Q | 37.76% | SMA20 | 13.46% ($19.29) | Beta | 3.29 | Target Price | $22.4 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/7/29 | SMA50 | 24.31% ($17.61) | Rel Volume | 1.52 | Prev Close | $21.43 |
| Employees | 423 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 8.78% 1.75% | SMA200 | 34.7% ($16.25) | Avg Volume(3M) | 1.29M | Price | $21.89 |
| IPO | 2025/1/30 | Option/Short | Yes/Yes | Trades | 8332 | Volume | 1,953,138 | Change | 2.15% |
Company
BBNX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩸 Beta Bionics (BBNX) is a US medical device company that develops and commercializes the iLet Bionic Pancreas, an automated insulin delivery system for insulin-dependent diabetes patients. With a simplified design that reduces complex manual calculations and enhances ease of use as its key differentiator, the company is rapidly expanding its footprint in the diabetes management device market.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
BBNX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -15.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 97.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XHE 0.01%
SGRW 0.00%
SNSR 0.00%
DWAS 0.00%
IHI 0.00%It ranks #4 in the industry
Based on market cap of $985M.
BBNX $985M PER -
ABT $178B PER 33.2
MDT $118B PER 22.7
SYK $106B PER 28.5
FAQ
What kind of company is BBNX?
BBNX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BBNX?
The market cap of BBNX is approximately $985M, ranking 2,647 within its sector.
What is the 52-week high and low for BBNX?
BBNX has recorded a 52-week high of $32.71 and a low of $8.80.
